La maladie de Parkinson au Canada (serveur d'exploration)

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Libération And NotAndres M. Lozano

List of bibliographic references

Number of relevant bibliographic references: 11.
Ident.Authors (with country if any)Title
000131 Anthony N. Carlsen [Canada] ; Dana Maslovat [Canada] ; Ian M. Franks [Canada]Preparation for voluntary movement in healthy and clinical populations: Evidence from startle : Neurophysiology of the Brainstem
000454 T. D. L. Steeves [Canada] ; J. Miyasaki [Canada] ; M. Zurowski [Canada] ; A. E. Lang [Canada] ; G. Pellecchia [Canada] ; T. Van Eimeren [Canada] ; P. Rusjan [Canada] ; S. Houle [Canada] ; A. P. Strafella [Canada]Increased striatal dopamine release in Parkinsonian patients with pathological gambling : a [11C] raclopride PET study
000632 Jessica M. Castellano [Canada] ; Jody Batrynchuk [Canada] ; Kristine Dolbeare [États-Unis] ; Vaneeta Verma [Canada] ; Amandeep Mann [Canada] ; Kevin J. Skoblenick [Canada] ; Rodney L. Johnson [États-Unis] ; Ram K. Mishra [Canada]MIF-1 and its peptidomimetic analogs attenuate haloperidol-induced vacuous chewing movements and modulate apomorphine-induced rotational behavior in 6-hydroxydopamine-lesioned rats
000633 Jessica M. Castellano [Canada] ; Jody Batrynchuk [Canada] ; Kristine Dolbeare [États-Unis] ; Vaneeta Verma [Canada] ; Amandeep Mann [Canada] ; Kevin J. Skoblenick [Canada] ; Rodney L. Johnson [États-Unis] ; Ram K. Mishra [Canada]MIF-1 and its peptidomimetic analogs attenuate haloperidol-induced vacuous chewing movements and modulate apomorphine-induced rotational behavior in 6-hydroxydopamine-lesioned rats
000712 Kaveh M. Koochesfahani [Canada] ; Raul De La Fuente-Fernandez [Canada, Espagne] ; Vesna Sossi [Canada] ; Michael Schulzer [Canada] ; Lakshmi N. Yatham [Canada] ; Thomas J. Ruth [Canada] ; Stephan Blinder [Canada] ; A. Jon Stoessl [Canada]Oral methylphenidate fails to elicit significant changes in extracellular putaminal dopamine levels in Parkinson's disease patients : Positron emission tomographic studies
000852 Raul De La Fuente-Fernandez [Canada, Espagne] ; Michael Schulzer [Canada] ; Edwin Mak [Canada] ; Donald B. Calne [Canada] ; A. Jon Stoessl [Canada]Presynaptic mechanisms of motor fluctuations in Parkinson's disease: a probabilistic model
000868 Raul De La Fuente-Fernandez [Canada] ; Vesna Sossi [Canada] ; ZHIGAO HUANG [Canada] ; Sarah Furtado [Canada] ; Jian-Qiang Lu [Canada] ; Donald B. Calne [Canada] ; Thomas J. Ruth [Canada] ; A. Jon Stoessl [Canada]Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias
000886 Gregory Dalbo [Canada] ; Fannie St-Gelais [Canada] ; Marc Danik [Canada] ; Sylvain Williams [Canada] ; Mathieu Cotton [Canada] ; Louis-Eric Trudeau [Canada]Dopamine neurons in culture express VGLUT2 explaining their capacity to release glutamate at synapses in addition to dopamine
000913 Antonio P. Strafella [Canada] ; Abbas F. Sadikot [Canada] ; Alain Dagher [Canada]Subthalamic deep brain stimulation does not induce striatal dopamine release in Parkinson's disease
000B07 Raul De La Fuente-Fernandez [Canada] ; Thomas J. Ruth [Canada] ; Vesna Sossi [Canada] ; Michael Schulzer [Canada] ; Donald B. Calne [Canada] ; A. Jon Stoessl [Canada]Expectation and dopamine release: Mechanism of the placebo effect in Parkinson's disease
000D24 C. J. Gibson [Canada] ; D. G. Munoz [Canada]Chromogranin A inhibits dopamine release from rat striatal slices

Wicri

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022